Talphera Q4 Earnings Call Highlights

Talphera (NASDAQ: TLPH) used a virtual analyst and investor event to provide a business update and to highlight what company leaders and two clinical experts described as an unmet need in anticoagulation during continuous renal replacement therapy (CRRT). The discussion focused on Talphera's ongoing NEPHRO CRRT registrational study of Niyad (nafamostat) and the practical limitations clinicians